Relative Uptake, Metabolism, and β-Receptor Binding of (1R,2S)-4

The objective of the study was to compare relative uptake, metabolism, and β-receptor affinity of the new positron-emitting uptake-1 tracer (1 R ,2 S )-4-18F-fluorometaraminol (4-FM) with those of the SPECT pharmaceutical meta-123I-iodobenzylguanidine (MIBG) in Wistar Kyoto (WKY) rats and spontaneously hypertensive (SHR) rats. Methods: No-carrier-added 4-18F-FM was applied to SHR and WKY rats in vivo and to retrogradely perfused hearts in vitro. Cardiac and extracardiac distribution was assessed, and metabolite formation was determined by thin-layer chromatography. The in vivo experiments were repeated with no-carrier-added 123I-MIBG. By means of autoradiography, the β-receptor affinity of 4-FM was compared with that of MIBG and propranolol (10 μmol/L) through displacement of 125I-iodocyanopindolol (1.5 pmol/L) in slices of heart and spleen. Results: Cardiomyopathic hearts showed heterogeneous 4-18F-FM uptake with gradients up to 3.6 in vivo and in vitro between different regions of the heart. Control hearts showed such gradients in 4-18F-FM uptake only in vitro. 123I-MIBG exhibited a less heterogeneous in vivo distribution in SHR hearts. Extracardiac differences between WKY and SHR were found for uptake of 4-18F-FM in the spleen (63.3% ± 4% vs. 38.8% ± 5.7% of cardiac activity) and for renal uptake of 123I-MIBG (373% ± 27% vs. 81.4% ± 17% of cardiac activity). Metabolites of 4-18F-FM were found only in the liver and those of 123I-MIBG were found in the liver and kidney with a nearly equal relative fraction in both types of animals of about 20%, 60%, and 30%, respectively. 4-FM suppressed cardiac-specific β-receptor binding of 125I-iodocyanopindolol in heart and spleen of both types of animals significantly, whereas MIBG had almost no effect. Conclusion: The more heterogeneous cardiac distribution of 4-18F-FM suggests that it reflects alterations in uptake-1 better than 123I-MIBG in addition to the possibility of quantification and higher spatial resolution by PET compared with SPECT. Altered biotransformation in cardiomyopathic diseases may also impair the evaluation of 123I-MIBG-SPECT data. The β-receptor binding of 4-18F-FM must be further elucidated.

Introduction to Lipids and Lipoproteins - Endotext - NCBI Bookshelf

Insulin receptor endocytosis in the pathophysiology of insulin resistance

IJMS, Free Full-Text

The role of solute binding proteins in signal transduction - ScienceDirect

Calcium homeostasis and cancer: insights from endoplasmic reticulum-centered organelle communications: Trends in Cell Biology

Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications

MAVS integrates glucose metabolism and RIG-I-like receptor signaling

A Metabolic Pathway for Activation of Dietary Glucosinolates by a Human Gut Symbiont - ScienceDirect

Metabolism and epigenetics at the heart of T cell function: Trends in Immunology

Frontiers Role of Glucagon and Its Receptor in the Pathogenesis of Diabetes

Relative Uptake, Metabolism, and β-Receptor Binding of (1R,2S)-4-18F-Fluorometaraminol and 123I-MIBG in Normotensive and Spontaneously Hypertensive Rats

G protein-coupled receptor-G protein interactions: a single-molecule perspective

Copper homeostasis and cuproptosis in health and disease

Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives